Literature DB >> 26711668

Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors.

Natalie Wee1, Nagaendran Kandiah2, Sanchalika Acharyya1, Russell J Chander3, Aloysius Ng3, Wing Lok Au2, Louis C S Tan4.   

Abstract

BACKGROUND: Depression and anxiety are common in Parkinson's disease (PD) and contribute significantly to a reduced quality of life in PD patients. Though they often co-exist, it is unclear whether depression and anxiety result from a shared pathological process. We studied the longitudinal course and determinants of depression and anxiety in PD in order to understand which factors contribute to the development of these symptoms.
METHODS: We conducted a prospective longitudinal study of 89 mild PD patients over 18 months, measuring depressive and anxiety symptoms at 6 monthly intervals using the Geriatric Depression Scale and Hospital Anxiety and Depression Scale--'Anxiety' subscale. Univariate and multivariate Generalised Estimating Equations were used to investigate the course of depression and anxiety and their association with demographic factors, motor measures, non-motor symptoms, and pharmacological factors.
RESULTS: Depression and anxiety were co-morbid in 13.5% of the sample. Depressive symptoms remained relatively stable while anxiety symptoms improved over the course of 18 months. Severity of depressive symptoms was associated with female gender, motor fluctuations, apathy, and anxiety, while severity of anxiety was associated with older age, higher educational attainment, shorter disease duration, younger age of disease onset, and excessive daytime sleepiness.
CONCLUSIONS: Although depression and anxiety are frequently co-morbid in PD, they were dissociable from each other. They had distinct trajectories and different longitudinal relationships with demographic, motor, and non-motor factors that were unique to each disorder.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Anxiety; Depression; Generalised Estimating Equations; Longitudinal; Non-motor; Parkinson's disease

Mesh:

Year:  2015        PMID: 26711668     DOI: 10.1016/j.parkreldis.2015.12.001

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

Review 1.  Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders.

Authors:  Luigi Trojano; Costanza Papagno
Journal:  Neurol Sci       Date:  2017-10-16       Impact factor: 3.307

Review 2.  The Relationship Between Anxiety Disorders and Parkinson's Disease: Clinical and Therapeutic Issues.

Authors:  Sandra Abou Kassm; Wadih Naja; Ramzi Haddad; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

Review 3.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

4.  Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease.

Authors:  Shi-Shuang Cui; Juan-Juan Du; Rao Fu; Yi-Qi Lin; Pei Huang; Ya-Chao He; Chao Gao; Hua-Long Wang; Sheng-Di Chen
Journal:  BMC Geriatr       Date:  2017-11-22       Impact factor: 3.921

5.  Family Functioning and Communication in Spouses of Patients with Parkinsonism.

Authors:  Seo Young Kang; Myung Hwa Yang; Jung Ah Lee; Wooyoung Jang; Chong Sik Lee; Young Sik Kim
Journal:  Korean J Fam Med       Date:  2017-01-18

6.  Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease.

Authors:  Motoki Okano; Kazue Takahata; Junya Sugimoto; Shizuko Muraoka
Journal:  Front Behav Neurosci       Date:  2019-08-02       Impact factor: 3.558

7.  Impact of Sex on the Nonmotor Symptoms and the Health-Related Quality of Life in Parkinson's Disease.

Authors:  Márton Kovács; Attila Makkos; Zsuzsanna Aschermann; József Janszky; Sámuel Komoly; Rita Weintraut; Kázmér Karádi; Norbert Kovács
Journal:  Parkinsons Dis       Date:  2016-05-16

Review 8.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

9.  Affective Disorder and Functional Status as well as Selected Sociodemographic Characteristics in Patients with Multiple Sclerosis, Parkinson's Disease and History of Stroke.

Authors:  Andrzej Knapik; Ewa Krzystanek; Justyna Szefler-Derela; Joanna Siuda; Jerzy Rottermund; Ryszard Plinta; Anna Brzęk
Journal:  Medicina (Kaunas)       Date:  2020-03-07       Impact factor: 2.430

Review 10.  Review of the neurological benefits of phytocannabinoids.

Authors:  Joseph Maroon; Jeff Bost
Journal:  Surg Neurol Int       Date:  2018-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.